Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
Result: M184V (8.4%, 20/239) and K103N (5.4%, 13/239) were the most frequent NRTI- and NNRTI-associated mutations respectively.
Result: The most frequent pattern was M184V only (36%, 9/25) resulting in HLR to lamivudine/emtricitabine, low-level resistance (LLR) to abacavir and potential low-level resistance (PLR) to didanosine.
Result: The mutational pattern, D67N-M41L-
Discussion: M184V is associated with high-level resistance to lamivudine and emtricitabine.
Discussion: As previously described, M184V was the most prevalent NRTI mutation occurring in all the 10 major mutational patterns reported in this study.
Analysis of HIV-1 diversity, primary drug resistance and transmission networks in Croatia.
Result: Also, one Croatian patient with a complex pattern of resistance (SDRM to PI: I84V + NRTI: M184MIV, T215S, L210W + NNRTI: K101E, Y181C, G190A, P225PH) was observed in a transmission pair with a Serbian sequence with a similar SDRM pattern with one additional SDRM (PI: M46I), indicating cross border transmission of multi-class drug resistance.
Survey of Pretreatment HIV Drug Resistance and Genetic Transmission Network Analysis Among HIV Patients in a High Drug-Use Area of Southwest China.
Method: The proportion of patients with M184 V/I, K103 N/S, and K65R mutations, as well as the presence of thymidine analogue mutations (TAMs) we
Discussion: Conversely, we observed a much lower frequency (4.3%) of M184 V/I resistance mutations among treatment-experienced patients than the provincial frequency of 30%, which may represent truly lower baseline rates or an underestimation due to M184 V/I's potential to be archived.
Discussion: Providers should initiate a first-line integrase-based cART regimen as soon as possible, recognizing that M184 V/I resistance mutations are rare (or possibly underestimated) and that NNRTIs should be avoided (as per current guidelines).
Elucidating molecular interactions of L-nucleotides with HIV-1 reverse transcriptase and mechanism of M184V-caused drug resistance.
Result: Alignment of RT-DNA and M184V-DNA structures resulted in an RMSD of 0.39 A.
Result: Although the calculated maximum likelihood coordinate error reported in Phenix refinement is 0.33 A for the WT and M184V (-)-FTC-TP structures, this shift is propagated to cause other atoms of (-)-FTC-TP to move more than 0.33 A from the WT structure.
Result: As expected, M184V incorporated dCTP (kp/Kd = 2.3 microM-1 s-1) with a similar efficiency to WT (kp/Kd = 1.9 microM-1 s-1) (Table 1).
Result: As in our previous work, single-turnover kinetic assays were performed by rapidly mixing a pre-incubating solution of 120 nM HIV-1 RT (WT or M184V) and 30 nM 5'-[32P]-labeled 18/26-mer dsDNA substrate (Methods) with varying concentrations of dCTP, or an active metabolite of
HIV-1 Reverse Transcriptase Promotes Tumor Growth and Metastasis Formation via ROS-Dependent Upregulation of Twist.
PMID: 31885806
2019
Oxidative medicine and cellular longevity
Method: Mutations M184V and K65R conferring resistance to nucleoside RT inhibitors (NRTI) and K103N and G190S conferring resistance to nonnucleoside RT inhibitors (NNRTI) were introduced into p6HRT_A by site-directed mutagenesis (Evrogen) generating plasmids p6HRT_An (65/184) and p6HRT_Ann (103/190), respectively.
Discussion: We designed the consensus RT of HIV-1 clade A FSU_A strain (RT_A) and two RT_A variants with primary mutations of resistance to NRTI (K65R and M184V; RT_An) and NNRTI (K103N
The association between detected drug resistance mutations and CD4(+) T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.
Abstract: Among individuals with at least one DRM, we found evidence that any nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance, the reverse transcriptase (RT) mutations M184V, D67N and T215Y as well as the protease mutations V82A and I54V were associated with reduced CD4 declines.
Comparison of antiretroviral drug resistance among treatment-naive and treated HIV-infected individuals in Shiraz, Iran.
Abstract: Regarding NRTI and NNRTI resistance mutations among treated patients, the most frequent mutation (7%) was M184 V, which causes high level resistance to zidovudin and emtricitabine.
Distinct Pattern of Thymidine Analogue Mutations with K65R in Patients Failing Tenofovir-Based Antiretroviral Therapy.
PMID: 29084434
2018
AIDS research and human retroviruses
Introduction: As expected, M184I/V was the most common NRTI mutation, present in 82.6% of patients at S1 and 96.8% at S2.
Introduction: In patients failing TDF-based therapy, the predominant NRTI DRM aside from M184I/V was K65R, which was present in 45/87 (51.7%) S1 and 56/87 (64.4%) S2 patients.
Introduction: In patients failing an AZT-containing regimen, TAMs were the most common DRMs after M184I/V.
Introduction: There was no significant difference in the prevalence of M184I/V at S1 or S2 between patients failing FTC or 3TC, or between patients with TDF or AZT exposure.
Characteristics of Treatment-experienced HIV-infected African Children and Adolescents Initiating Darunavir and/or Etravirine-based Antiretroviral Treatment.
PMID: 29140932
2018
The Pediatric infectious disease journal
Abstract: Forty seven patients (98.9%) had HIV genotype results: 41 (87.2%) had >=1 nucleos(t)ide reverse transcriptase inhibitor (NRTI)-resistance mutation (RM), predominantly M184V (76.6%; n = 36); 31 (65.9%) had >=1 non-NRTI-RM, including 27 (57.4%) with >=1 ETR-RM; 30 (63.8%) had >=3 protease inhibitor RM, including 20 (42.6%) with >=1 DRV-RM.
HIV mutation literature information.
PMID: 
2019
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT